Funds › Ikarian Capital, LLC
Ikarian Capital, LLC
13F for Q2 2026, filed Aug 14, 2026. 126 positions worth $928.2M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$928.2M
−$303.5M (24.6%) vs Q1 2026
Positions
126
127 in Q1 2026
Top 10 share
26.0%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Ikarian Capital, LLC in the latest 13F quarter?
Using 13F.ai, how has Ikarian Capital, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Ikarian Capital, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | ABVX Abivax SA · ADR | 328,635 | $43.4M | 4.7% | +470% | 13F ↗ |
| 2 | KOD Kodiak Sciences Inc | 1.06M | $41.3M | 4.4% | -16.3% | 13F ↗ |
| 3 | ALMS Alumis Inc. | 870,548 | $24.5M | 2.6% | -28.3% | 13F ↗ |
| 4 | PRAX Praxis Precision Medicines, Inc. | 72,842 | $24.4M | 2.6% | +1.8% | 13F ↗ |
| 5 | PCVX Vaxcyte, Inc. | 388,682 | $22.6M | 2.4% | -9.3% | 13F ↗ |
| 6 | ANIP ANI Pharmaceuticals, Inc. | 272,085 | $22.5M | 2.4% | +85.0% | 13F ↗ |
| 7 | CLDX Celldex Therapeutics, Inc. | 478,500 | $17.8M | 1.9% | +3.7% | 13F ↗ |
| 8 | RCUS Arcus Biosciences, Inc. | 504,559 | $15.6M | 1.7% | New | 13F ↗ |
| 9 | RLMD Relmada Therapeutics, Inc. | 2.15M | $14.9M | 1.6% | -20.1% | 13F ↗ |
| 10 | CAPR Capricor Therapeutics, Inc. | 604,215 | $14.5M | 1.6% | +14.4% | 13F ↗ |
| 11 | COGT Cogent Biosciences, Inc. | 370,084 | $14.3M | 1.5% | New | 13F ↗ |
| 12 | VERA Vera Therapeutics, Inc. | 310,000 | $13.3M | 1.4% | +55.0% | 13F ↗ |
| 13 | CTNM Contineum Therapeutics, Inc. | 807,874 | $13.2M | 1.4% | Unchanged | 13F ↗ |
| 14 | TENX Tenax Therapeutics, Inc. | 787,600 | $11.5M | 1.2% | -22.6% | 13F ↗ |
| 15 | CCCC C4 Therapeutics, Inc. | 2.43M | $11.4M | 1.2% | New | 13F ↗ |
| 16 | MAZE Maze Therapeutics, Inc. | 378,999 | $11.3M | 1.2% | Unchanged | 13F ↗ |
| 17 | BHVN Biohaven Ltd. | 748,181 | $11.1M | 1.2% | +81.4% | 13F ↗ |
| 18 | CNTB Connect Biopharma Holdings Limited | 4.54M | $10.8M | 1.2% | -15.8% | 13F ↗ |
| 19 | ANRO Alto Neuroscience, Inc. | 407,338 | $10.7M | 1.2% | -20.9% | 13F ↗ |
| 20 | PHVS Pharvaris N.V. | 308,856 | $10.7M | 1.2% | -36.6% | 13F ↗ |
| 21 | JBIO Jade Biosciences, Inc. | 427,349 | $9.5M | 1.0% | -16.6% | 13F ↗ |
| 22 | Damora Therapeutics Inc | 335,710 | $8.7M | 0.9% | Unchanged | 13F ↗ |
| 23 | VRDN Viridian Therapeutics, Inc. | 425,000 | $7.8M | 0.8% | New | 13F ↗ |
| 24 | PTHS Pelthos Therapeutics Inc. | 256,598 | $7.3M | 0.8% | Unchanged | 13F ↗ |
| 25 | ZURA Zura Bio Limited | 1.22M | $7.2M | 0.8% | +2.1% | 13F ↗ |
| 26 | TECX Tectonic Therapeutic, Inc. | 205,837 | $7.1M | 0.8% | +30.7% | 13F ↗ |
| 27 | SPRB Spruce Biosciences, Inc. | 121,356 | $6.6M | 0.7% | Unchanged | 13F ↗ |
| 28 | HIMS Hims & Hers Health, Inc. | 188,381 | $6.5M | 0.7% | New | 13F ↗ |
| 29 | ELVN Enliven Therapeutics, Inc. | 126,541 | $6.4M | 0.7% | New | 13F ↗ |
| 30 | PRQR ProQR Therapeutics N.V. · Shs Euro | 3.43M | $6.4M | 0.7% | +130% | 13F ↗ |
| 31 | DRUG Bright Minds Biosciences Inc. | 88,951 | $6.2M | 0.7% | -46.6% | 13F ↗ |
| 32 | OVID Ovid Therapeutics Inc. | 2.27M | $6.1M | 0.7% | -21.6% | 13F ↗ |
| 33 | OCGN Ocugen, Inc. | 3.96M | $6.1M | 0.7% | Unchanged | 13F ↗ |
| 34 | ACOG Alpha Cognition Inc. | 836,259 | $6.0M | 0.7% | -20.8% | 13F ↗ |
| 35 | HROW Harrow, Inc. | 135,775 | $5.8M | 0.6% | -75.0% | 13F ↗ |
| 36 | KZIA Kazia Therapeutics Limited · ADR | 396,201 | $5.6M | 0.6% | New | 13F ↗ |
| 37 | RARE Ultragenyx Pharmaceutical Inc. | 165,617 | $5.5M | 0.6% | -65.7% | 13F ↗ |
| 38 | QTTB Q32 Bio Inc. | 430,000 | $5.5M | 0.6% | New | 13F ↗ |
| 39 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 809,741 | $5.4M | 0.6% | -33.3% | 13F ↗ |
| 40 | BIOA BioAge Labs, Inc. | 200,000 | $4.9M | 0.5% | New | 13F ↗ |
| 41 | RZLT Rezolute, Inc. | 935,012 | $4.9M | 0.5% | +5574% | 13F ↗ |
| 42 | OLMA Olema Oncology, Inc. | 383,281 | $4.8M | 0.5% | -35.9% | 13F ↗ |
| 43 | MNPR Monopar Therapeutics Inc. | 47,861 | $4.4M | 0.5% | New | 13F ↗ |
| 44 | BBIO BridgeBio Pharma, Inc. | 57,417 | $4.3M | 0.5% | -64.1% | 13F ↗ |
| 45 | IVA Inventiva S.A. · ADR | 1.13M | $4.2M | 0.4% | -21.0% | 13F ↗ |
| 46 | ABSI Absci Corporation | 353,772 | $4.1M | 0.4% | New | 13F ↗ |
| 47 | ALEC Alector, Inc. | 1.98M | $4.0M | 0.4% | -4.8% | 13F ↗ |
| 48 | CLYM Climb Bio, Inc. | 300,000 | $3.9M | 0.4% | New | 13F ↗ |
| 49 | FULC Fulcrum Therapeutics, Inc. | 1.05M | $3.8M | 0.4% | Unchanged | 13F ↗ |
| 50 | CRDL Cardiol Therapeutics Inc. | 3.33M | $3.5M | 0.4% | +22.0% | 13F ↗ |
Showing the top 50 of 126 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
27 new, 18 added to, 29 trimmed, 28 exited, 52 unchanged. By estimated dollars.
New positions (27)
| RCUS Arcus Biosciences, Inc. | 504,559 | New | $15.6M |
| COGT Cogent Biosciences, Inc. | 370,084 | New | $14.3M |
| CCCC C4 Therapeutics, Inc. | 2.43M | New | $11.4M |
| VRDN Viridian Therapeutics, Inc. | 425,000 | New | $7.8M |
| HIMS Hims & Hers Health, Inc. | 188,381 | New | $6.5M |
| ELVN Enliven Therapeutics, Inc. | 126,541 | New | $6.4M |
| KZIA Kazia Therapeutics Limited · ADR | 396,201 | New | $5.6M |
| QTTB Q32 Bio Inc. | 430,000 | New | $5.5M |
| BIOA BioAge Labs, Inc. | 200,000 | New | $4.9M |
| MNPR Monopar Therapeutics Inc. | 47,861 | New | $4.4M |
Added to (18)
| ABVX Abivax SA · ADR | 328,635 | +470% | $35.7M |
| ANIP ANI Pharmaceuticals, Inc. | 272,085 | +85.0% | $10.3M |
| BHVN Biohaven Ltd. | 748,181 | +81.4% | $5.0M |
| RZLT Rezolute, Inc. | 935,012 | +5574% | $4.8M |
| VERA Vera Therapeutics, Inc. | 310,000 | +55.0% | $4.7M |
| PRQR ProQR Therapeutics N.V. · Shs Euro | 3.43M | +130% | $3.6M |
| PMN ProMIS Neurosciences Inc. | 205,000 | +273% | $2.0M |
| CAPR Capricor Therapeutics, Inc. | 604,215 | +14.4% | $1.8M |
| TECX Tectonic Therapeutic, Inc. | 205,837 | +30.7% | $1.7M |
| PALI Palisade Bio, Inc. | 750,000 | +173% | $992.8K |
Trimmed (29)
| HROW Harrow, Inc. | 135,775 | -75.0% | -$17.3M |
| RARE Ultragenyx Pharmaceutical Inc. | 165,617 | -65.7% | -$10.6M |
| ALMS Alumis Inc. | 870,548 | -28.3% | -$9.7M |
| CMPS COMPASS Pathways Plc · ADR | 15,000 | -97.8% | -$9.3M |
| KOD Kodiak Sciences Inc | 1.06M | -16.3% | -$8.0M |
| BBIO BridgeBio Pharma, Inc. | 57,417 | -64.1% | -$7.6M |
| PHVS Pharvaris N.V. | 308,856 | -36.6% | -$6.2M |
| DRUG Bright Minds Biosciences Inc. | 88,951 | -46.6% | -$5.5M |
| RLMD Relmada Therapeutics, Inc. | 2.15M | -20.1% | -$3.7M |
| TENX Tenax Therapeutics, Inc. | 787,600 | -22.6% | -$3.3M |
Exited (28)
| Terns Pharmaceuticals Inc | 1.46M | Exited | -$76.8M |
| CYTK Cytokinetics, Incorporated | 283,572 | Exited | -$18.7M |
| RVMD Revolution Medicines, Inc. | 163,142 | Exited | -$15.9M |
| ORKA Oruka Therapeutics, Inc. | 242,021 | Exited | -$11.9M |
| Soleno Therapeutics Inc | 344,123 | Exited | -$11.5M |
| IONS Ionis Pharmaceuticals, Inc. | 127,038 | Exited | -$9.5M |
| PVLA Palvella Therapeutics, Inc. | 64,626 | Exited | -$8.1M |
| LLY Eli Lilly and Company | 6,547 | Exited | -$6.0M |
| SRZN Surrozen, Inc. | 173,107 | Exited | -$5.0M |
| LEGN Legend Biotech Corporation · ADR | 226,888 | Exited | -$4.1M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer